SCHEMBL7080798

SCHEMBL7080798

C=C(C)CCNc1ncnc2nc[nH]c12.Cn1c(N)nc2nc[nH]c2c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.47
CYP3A4 P08684 2/20 0.47
LMNA P02545 4/20 0.45
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
CYP1A2 P05177 3/20 0.44
CDK2 P24941 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TSHR P16473 5/20 0.42
HSD17B10 Q99714 4/20 0.42
RECQL P46063 1/20 0.42
TP53 P04637 2/20 0.41
EPHB2 P29323 1/20 0.41
HIF1A Q16665 1/20 0.41
PRMT1 Q99873 2/20 0.41
MAPK1 P28482 2/20 0.41
TAAR1 Q96RJ0 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29359033 0.83 HTT (0.67) HTTCYP3A4LMNAHDAC1HDAC2
SCHEMBL101602 0.83 HTT (0.67) HTTCYP3A4LMNAHDAC1HDAC2
Hydrochloric Acid SCHEMBL30150738 0.82 HTT (0.65) HTTCYP3A4LMNAHDAC1HDAC2
SCHEMBL20867 0.75 ATAD2 (0.53) CYP3A4LMNACYP1A2TSHRHIF1A
Water SCHEMBL27738785 0.74 ADORA2A (0.54) CYP3A4LMNACYP1A2TSHRHIF1A
Hydrochloric Acid SCHEMBL27339406 0.74 ATAD2 (0.51) CYP3A4LMNACYP1A2TSHRHIF1A
SCHEMBL27602647 0.72 ATAD2 (0.49) CYP3A4LMNACYP1A2TSHRHIF1A
SCHEMBL29249244 0.71 CYP3A4 (0.45) HTTCYP3A4LMNAHDAC1HDAC2
SCHEMBL28996851 0.71 CYP1A2 (0.55) HTTCYP3A4LMNAHDAC1HDAC2
SCHEMBL29404312 0.71 CYP3A4 (0.67) HTTCYP3A4HDAC1HDAC2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003070763-A1 METHODS AND COMPOSITIONS FOR TREATING METABOLIC BONE DISEASES RELATING TO HUMAN ENDOKINE ALPHA HUMAN GENOME SCIENCES, INC. (US) 2003-08-28 WO disclosed